Endocrine therapy for breast cancer: an overview

Breast

Volumn 16, Issue 4, 2007, Pages 327-343

  Cheung, K L ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Breast cancer; Endocrine therapy

Indexed keywords

21 (4 DIETHYLAMINOMETHYL 2 METHOXYPHENOXY) 7ALPHA METHYL 19 NORPREGNA 1,3,5(10) TRIEN 3 OL; AMINOGLUTETHIMIDE; ANASTROZOLE; ANTHRACYCLINE; ANTIESTROGEN; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CYCLOPHOSPHAMIDE; DIETHYLSTILBESTROL; ESTROGEN; ESTROGEN RECEPTOR; ETHINYLESTRADIOL; EXEMESTANE; FLUOROURACIL; FULVESTRANT; GEFITINIB; GESTAGEN; GONADORELIN AGONIST; GOSERELIN; HYDROCORTISONE; LETROZOLE; MEGESTROL ACETATE; METHOTREXATE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TRASTUZUMAB; UNINDEXED DRUG; ZOLEDRONIC ACID;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CEREBROVASCULAR DISEASE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; ENDOMETRIUM CARCINOMA; FRACTURE; HEART DISEASE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; LETHARGY; LIBIDO DISORDER; MONOTHERAPY; MUSCULOSKELETAL DISEASE; OVARIECTOMY; PHARMACOLOGICAL BLOCKING; PREMENOPAUSE; PREOPERATIVE CARE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; THROMBOEMBOLISM; VAGINA DISEASE; VENOUS THROMBOEMBOLISM; WEIGHT GAIN;

EID: 34547199941     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2007.03.004     Document Type: Review

References (136)

1. Beatson G. On the treatment of inoperable cases of carcinoma of the mamma: suggestion for a new method of treatment, with illustrative cases. Lancet 2 (1896) 104-107
2. Engelsman E., et al. Human breast cancer and estrogen receptor. Arch Chir Neerl 25 (1973) 393-397
3. Cole M., Jones C., and Todd I. A new antioestrogenic agent in late breast cancer. An early appraisal of ICI 46,474. Br J Cancer 25 (1971) 270-275
4. Knight W., et al. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37 (1977) 4669-4671
5. Maynard P., et al. Estrogen receptor assay in primary breast cancer and early recurrence of the disease. Cancer Res 38 (1978) 4292-4295
6. Osborne C., et al. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46 (1980) 2884-2888
7. Croton R., et al. Oestrogen receptors and survival in early breast cancer. Br Med J 283 (1981) 1289-1291
8. Cummings S., Eckert S., Krueger K., et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. J Am Med Assoc 281 (1999) 2189-2197
9. Howell A., Barnes D., Harland R., et al. Steroid-hormone receptors in survival after first relapse in breast cancer. Lancet 1 (1984) 588-591
10. Hawkins R., White G., Bundred N., et al. Prognostic significance of oestrogen and progesterone receptor activities in breast cancer. Br J Surg 74 (1987) 1009-1913
11. Williams M., Todd J., Ellis I., et al. Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases. Br J Cancer 55 (1987) 67073
12. Thorpe S. Estrogen and progesterone receptor determinations in breast cancer. Technology, biology and clinical significance. Acta Oncol 27 (1988) 1-19
13. Cheung K, et al. Pathological features of primary breast cancer in the elderly-a large series from a single centre. Scientific Programme of the Winter Scientific Meeting of the Pathological Society of Great Britain and Ireland, 2007. p. 54.
14. Allegra J., et al. Changes in multiple or sequential estrogen receptor determinations in breast cancer. Cancer 45 (1980) 792-794
15. Samaan N., Buzdar A., Aldinger K., et al. Estrogen receptor-a prognostic factor in breast cancer. Cancer 47 (1981) 554-560
16. Speirs V., et al. Increased expression of estrogen receptor β mRNA in tamoxifen-resistant breast cancer patients. Cancer Res 59 (1999) 5421-5424
17. Dutertre M., and Smith C. Molecular mechanisms of selective estrogen receptor modulator action. J Pharmacol Exp Ther 295 (2000) 431-437
18. Howell T. New endocrine agents. Cancer Treat Rev 23 (1997) S49-S57
19. Hayward J., et al. Assessment of response to therapy in advanced breast cancer. Cancer 39 (1977) 1289-1293
20. British Breast Group. Assessment of response to treatment in advanced breast cancer. Lancet 2 (1974) 38-39
21. Therasse P., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
22. Whitlock J., et al. Imaging of metastatic breast cancer: distribution and radiological assessment of involved sites at presentation. Clin Oncol 3 (2001) 181-186
23. American Society of Clinical Oncology. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 14 (1996) 2843-2877
24. Breast Specialty Group of the British Association of Surgical Oncology. The guidelines for the management of metastatic bone disease in breast cancer in the United Kingdom. Eur J Surg Oncol 25 (1999) 3-23
25. Cheung K., Evans A., and Robertson J. The use of blood tumour markers in the monitoring of metastatic breast cancer unassessable for response to systemic therapy. Breast Cancer Res Treat 67 (2001) 273-278
26. Cheung K., and Robertson J. The importance of stable disease in breast cancer patients treated with endocrine therapy. Breast Cancer Abstr 1 (1999) 2-4
27. Howell A., Mackintosh J., Jones M., et al. The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Cancer Clin Oncol 24 (1988) 1267-1272
28. Robertson J., et al. Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy. Eur J Cancer Clin Oncol 25 (1989) 469-475
29. Robertson J., et al. The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer. Eur J Cancer Clin Oncol 33 (1997) 1774-1779
30. Robertson J., et al. Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer. Breast Cancer Res Treat 58 (1999) 157-162
31. Cheung K., Willsher P., Pinder S., et al. Predictors of response to second-line endocrine therapy for breast cancer. Breast Cancer Res Treat 45 (1997) 219-224
32. Buzdar A., et al. Arimidex Study Group: a phase III trial comparing anastrozole (1 and 10 mgs), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Cancer 79 (1997) 730-739
33. Buzdar A., Jonat W., Howell A., et al. Arimidex Study Group: Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer 83 (1998) 1142-1152
34. Dombernowsky P., Smith I., Falskon R., et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16 (1998) 453-461
35. Goss P., et al. Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. J Clin Oncol 17 (1999) 52-63
36. Cheung K., Howell A., and Robertson J. Preoperative endocrine therapy for breast cancer. Endocr-Relate Cancer 7 (2000) 131-141
37. Ingle J., Ahmann D., Green S., et al. Randomised clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer. Am J Clin Oncol 5 (1982) 155-160
38. Smith I., Harris A., Morgan M., et al. Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomised cross-over trial. Br Med J 283 (1981) 1432-1434
39. Smith I., Harris A., Morgan M., et al. Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma. Cancer Res 42 (1982) 3430-3433
40. Ettinger D., Allegra J., Bertino J., et al. Megestrol acetate versus tamoxifen in advanced breast cancer: correlation of hormone receptors and response. Sem Oncol 13 Suppl 4 (1986) 9-14
41. Bonneterre J., Thurlimann D., Robertson J., et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex randomized group efficacy and tolerability study. J Clin Oncol 18 (2000) 3748-3757
42. Thurlimann B., et al. Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. Eur J Cancer Clin Oncol 39 (2003) 2310-2317
43. Kaufmann M., et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 18 (2000) 1399-1411
44. Lonning P., et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 18 (2000) 2234-2244
45. Bertelli G., et al. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology 69 (2005) 471-477
46. Nabholtz J., et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 18 (2000) 3758-3767
47. Milla-Santos A., et al. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study. Am J Clin Oncol 26 (2003) 317-322
48. Mouridsen H., et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19 (2001) 2596-2606
49. Eirmann W., et al. Letrozole Neo-Adjuvant Breast Cancer Study Group: Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 12 (2001) 1527-1532
50. Paridaens R., et al. European Organisation for the Research and Treatment of Cancer (EORTC)-Investigational Drug Branch for Breast Cancer (IDBBC). Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 14 (2003) 1391-1398
51. Robertson J., et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 98 (2003) 229-238
52. Osborne C., et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20 (2002) 3386-3395
53. Howell A., et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20 (2002) 3396-3403
54. Cheung K., Owers R., and Robertson J. Endocrine response after prior treatment with fulvestrant for postmenopausal women with advanced breast cancer: experience from a single centre. Endocr-Relat Cancer 13 (2006) 251-255
55. Mouridsen H., Palshof R., and Rose C. Therapeutic effect of tamoxifen alone versus tamoxifen in combination with gestagen and oestrogen in advanced breast cancer. In: Henningsden L.F.D., and Steichele C. (Eds). Endocrine treatment of breast cancer (1980), Springer, New York 169-177
56. Powles T., Ashley S., Ford H., et al. Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone and danazol used in combination or sequentially. Lancet 2 (1984) 1369-1373
57. Rose C., Kamby C., Mouridsen H., et al. Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomised trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone. Breast Cancer Res Treat 7 Suppl. (1986) 45-50
58. R) therapy in premenopausal women with breast cancer. Br J Surg 76 (1989) 1262-1265
59. Boccardo F., Rubagotti A., and Perrotta A.E.A. Ovarian ablation versus goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer: results of a multicentre Italian study. Ann Oncol 5 (1994) 337-342
60. Jonat W., Kaufmann M., Blamey R., et al. A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. Eur J Cancer Clin Oncol A-31 (1995) 137-142
61. Klijn J., et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst 92 (2000) 903-911
62. Klijn J., et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 19 (2001) 343-353
63. Carlson R., et al. Goserelin plus anastrozole for the treatment of premenopausal women with hormone receptor positive, recurrent/metastatic breast cancer. Breast Cancer Res Treat 88 Suppl 1 (2004)
64. Cheung K., et al. Goserelin plus anastrozole as first-line endocrine therapy for premenopausal women with oestrogen receptor positive advanced breast cancer. J Clin Oncol 23 16S (2005) 60s
65. Forward D., et al. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 90 (2004) 590-594
66. Early Breast Cancer Trialists Collaborative Group. Ovarian ablation in early breast cancer: an overview of the randomised trials. Lancet 348 (1996) 1189-1196
67. Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 (1998) 1451-1467
68. Early Breast Cancer Trialists Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352 (1998) 930-942
69. Early Breast Cancer Trialists Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
70. Ejlertsen B, Dombernowsky P, Mouridsen H, et al. Comparable effect of ovarian ablation and CMF chemotherapy in premenopausal hormone receptor positive breast cancer patients. In: Proceedings of ASCO annual scientific meeting, 1999.
71. Jakesz R., Hausmaninger H., Kubista E., et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer: Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 20 (2002) 4621-4627
72. Jonat W., et al. Zoladex Early Breast Cancer Research Association Study: Goserelin versus cyclophosphamide, methotrexate and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer. J Clin Oncol 20 (2002) 4628-4635
73. Scottish Cancer Trials Breast Group & ICRF Breast Unit Guy's Hospital London. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Lancet 341 (1993) 1293-1298
74. Kaufmann M., et al. Survival analyses from the ZEBRA study: Goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer 39 (2003) 1711-1717
75. Schmid P., et al. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients; Preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate). Anticancer Res 22 (2002) 2325-2332
76. Roche H, et al. Complete hormonal blockade versus chemotherapy in premenopausal early stage breast cancer patients with positive hormone-receptor and 1-3 node-positive tumor: results of the FASG06 trial. In: Proceedings of ASCO annual scientific meeting, 2000.
77. Castiglione-Gertsch M., et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 95 (2003) 1833-1846
78. Cuzick J. The impact of LHRH agonists on breast cancer recurrence and mortality: an overview of the randomized trials. Breast Cancer Res Treat 100 Suppl. 1 (2006) S10
79. Saphner T., Tormey D., and Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14 (1996) 2738-2746
80. Howell A., et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
81. Thurlimann B., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 (2005) 2747-2757
82. Coates A., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of Study BIG 1-98. J Clin Oncol 25 (2007) 486-492
83. Jakesz R., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 (2005) 455-462
84. Goss P., Ingle J., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349 (2003) 1793-1802
85. Coombes R., Hall E., Gibson L., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 (2004) 1081-1092
86. Boccardo F., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial. J Clin Oncol 23 (2005) 5138-5147
87. Mamounas E., et al. Benefit from exemestane as extended adjuvant therapy after 5 years of tamoxifen: intent-to-treat analysis of NSABP B-33. Breast Cancer Res Treat 100 Suppl (2006) S22
88. Jones J., Vukelja S., Cantrell J., et al. A planned comparison of menopausal symptoms during year one in patients receiving either exemestane or tamoxifen in a double-blind adjuvant hormone study. Breast Cancer Res Treat 82 (2003) S31
89. Aapro M. Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: The Z-ZO-E-ZO-FAST program. Breast 15 (2006) 30-40
90. Dowsett M. Group, obotAT, Analysis of time to recurrence in the ATAC (arimidex, tamoxifen, alone or in combination) trial according to estrogen and progesterone receptor status. Breast Cancer Res Treat 82 (2003) S7
91. Ellis M., Coop S., Singh B., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19 (2001) 3808-3816
92. Wengstrom Y., et al. Women's experience and knowledge of adjuvant endocrine therapy for early breast cancer: a European survey (2006), ESMO, Istanbul
93. Wengstrom Y., et al. Differences in older versus younger women's experience and knowledge of adjuvant endocrine therapy for early breast cancer (2006), SIOG, The Netherlands
94. Fisher B., Saffer E., Rudock C., et al. Presence of a growth stimulating factor in serum following primary tumor removal in mice. Cancer Res 49 (1989) 1996-2001
95. Fisher B., Saffer E., Rudock C., et al. Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth stimulating factor in mice. Cancer Res 49 (1989) 2002-2004
96. De Friend D., Howell A., and Nicholson R.E.A. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 15 (1994) 408-414
97. Ellis P., Saccani-Jotti G., and Clarke R.E.A. Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer. Int J Cancer 72 (1997) 608-613
98. Dowsett M., Lu Y., Hills M., et al. Effect of raloxifene on Ki67 and apoptosis. Breast Cancer Res Treat 57 (1999) 31
99. Dixon J., Love C., Tucker S., et al. Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat 46 (1997) 213
100. Dixon J., et al. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin Cancer Res 6 (2000) 2229-2235
101. Howell A., Anderson E., Blamey R., et al. The primary use of endocrine therapies. Recent Results Cancer Res 152 (1998) 227-244
102. Fisher B. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90 (1998) 1371-1388
103. Powles T., Eeles R., Ashley S., et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352 (1998) 98-101
104. Veronesi U. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 352 (1998) 93-97
105. Cuzick J., et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360 (2002) 817-824
106. Veronesi U., et al. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 92 (2003) 160-165
107. Cuzick J. Long term efficacy of tamoxifen for chemoprevention-results of the IBIS-I study. Breast Cancer Res Treat 100 Suppl. 1 (2006) S16-S17
108. Land S., et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. J Am Med Assoc 295 (2006) 2742-2751
109. Vogel V., et al. Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. J Am Med Assoc 295 (2006) 2727-2741
110. Vogel V., et al. The effects of tamoxifen versus raloxifene on the risk of developing noninvasive breast cancer in the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. Breast Cancer Res Treat 100 Suppl. 1 (2006) S16
111. Farrow J., and Adair F. Effect of orchidectomy on skeletal metastasis from cancer of the male breast. Science 95 (1942) 654
112. Ying M., Agrawal A., and Cheung K. The 'other half' of breast cancer-a review of male breast cancer. J Men's Health Gender 2 (2005) 406-413
113. Harris A., et al. Role of aminoglutethimide in male breast cancer. Br J Cancer 54 (1986) 657-660
114. Jaiyesimi I., et al. Carcinoma of the male breast. Ann Int Med 117 (1992) 771-777
115. Anelli T., et al. Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients. Cancer 74 (1994) 74-77
116. Griffin J., and Wilson J. Disorders of the testes and the male reproductive tract. In: Larsen R., et al. (Ed). Williams textbook of endocrinology (2003), Saunders, Philadelphia, PA 709-769
117. Zabolotny B., Zalai C., and Meterissian S. Successful use of letrozole in male breast cancer: a case report and review of hormonal therapy for male breast cancer. J Surg Oncol 90 (2005) 26-30
118. Agrawal A., et al. Fulvestrant in advanced male breast cancer. Breast Cancer Res Treat 101 (2007) 123
119. Labrie F., et al. Complete response to combination therapy with an LHRH agonist and flutamide in metastatic male breast cancer: a case report. Clin Invest Med 13 (1990) 275-278
120. Cheung K., et al. Primary endocrine therapy with anastrozole for early operable primary breast cancer in the elderly-early clinical and biological data. J Clin Oncol 24 (2006) 18S
121. Agrawal A., et al. Resurrection of clinical efficacy after resistance to endocrine therapy in metastatic breast cancer. World J Surg Oncol 4 (2006) 40
122. Robertson J., et al. Onapristone, a progesterone receptor antagonist, as first line therapy in primary breast cancer. Eur J Cancer Clin Oncol 35 (1999) 214-218
123. Crook S, Brook D, Robertson J. Biological and molecular mechanism of the progesterone receptor antagonist, onapristone. In: Proceedings of AACR annual scientific meeting, 2001.
124. Buzdar A. TAS-108: a novel steroidal antiestrogen. Clin Cancer Res 11 (2005) 906s-908s
125. Ingle J., et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 304 (1981) 16-21
126. Agrawal A., Robertson J., and Cheung K. Efficacy and tolerability of high dose ethinylestradiol in post-menopausal advanced breast cancer patients heavily pre-treated with endocrine agents. World J Surg Oncol 4 (2006) 44
127. Lonning P., et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 67 (2001) 111-116
128. Agrawal A., Robertson J., and Cheung K. Clinical relevance of "withdrawal therapy" from anti-oestrogens in breast cancer. Eur J Surg Oncol 32 (2006) 1035
129. Puddefoot J., et al. Non-competitive steroid inhibition of oestrogen receptor functions. Int J Cancer 101 (2002) 17-22
130. Kenny F., Pinder S., and Ellis I. Gamma linolenic acid with tamoxifen as primary therapy in breast cancer. Int J Cancer 85 (2000) 643-648
131. Robertson J, et al. Gefitinib (Iressa, ZD1839) is active in acquired tamoxifen-resistant oestrogen receptor-positive and oestrogen receptor-negative breast cancer: results from a Phase II study. In: Proceedings of ASCO annual scientific meeting, 2003.
132. Mackey J., et al. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. Breast Cancer Res Treat 100 Suppl. 1 (2006) S5-S6
133. Cheung K., et al. Selection of primary breast cancer patients for adjuvant endocrine therapy-is oestrogen receptor alone adequate?. Breast Cancer Res Treat 85 (2001) 155-162
134. Hui R., Cornish A., McClelland R., et al. Cyclin DI and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer. Clin Cancer Res 2 (1996) 923-928
135. Hui R., Ball J., Macmillan R., et al. EMSI gene expression in primary breast cancer: relationship cyclin D1 and oestrogen receptor expression and patient survival. Oncogene 17 (1998) 1053-1059
136. Kenny F., Hui R., Musgrove E., et al. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res 5 (1999) 2069-2076